Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer

ByAndy Studna, Senior Editor

October 17th 2025

Adaptive Trial Design as a Pathway to Faster Development

ByBen Edwards,Andy Studna, Senior Editor

October 17th 2025

After the Trial is too Late: The Case for More Active Use of Patient-Reported Outcomes in Oncology Studies

ByJens Lehmann, PhD

October 16th 2025

© Creative Cat Studio - © Creative Cat Studio - stock.adobe.com

Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor

ByAndy Studna, Senior Editor

October 16th 2025

Setting the Limits of Autonomy with Autonomous Agents for Clinical Research

ByAndrew Mackinnon,Alison Holland

October 16th 2025

Act cover

Articles in this issue

Newsletter

Related Content

Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer

Adaptive Trial Design as a Pathway to Faster Development

After the Trial is too Late: The Case for More Active Use of Patient-Reported Outcomes in Oncology Studies

Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor

Setting the Limits of Autonomy with Autonomous Agents for Clinical Research

Trending on Applied Clinical Trials Online

Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer

Adaptive Trial Design as a Pathway to Faster Development

Applied Clinical Trials: October 2025 Interactive Digital Edition

After the Trial is too Late: The Case for More Active Use of Patient-Reported Outcomes in Oncology Studies

In With the New